These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 30963603)
21. Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. Capurro MI; Shi W; Sandal S; Filmus J J Biol Chem; 2005 Dec; 280(50):41201-6. PubMed ID: 16227623 [TBL] [Abstract][Full Text] [Related]
22. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma. Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714 [TBL] [Abstract][Full Text] [Related]
23. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Midorikawa Y; Ishikawa S; Iwanari H; Imamura T; Sakamoto H; Miyazono K; Kodama T; Makuuchi M; Aburatani H Int J Cancer; 2003 Feb; 103(4):455-65. PubMed ID: 12478660 [TBL] [Abstract][Full Text] [Related]
25. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling. Quan H; Li B; Yang J Biomed Pharmacother; 2018 Nov; 107():754-762. PubMed ID: 30142536 [TBL] [Abstract][Full Text] [Related]
26. Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells. Saad A; Liet B; Joucla G; Santarelli X; Charpentier J; Claverol S; Grosset CF; Trézéguet V Biochemistry; 2018 Feb; 57(7):1201-1211. PubMed ID: 29345911 [TBL] [Abstract][Full Text] [Related]
27. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma. Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263 [TBL] [Abstract][Full Text] [Related]
28. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074 [TBL] [Abstract][Full Text] [Related]
29. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β‑catenin signaling pathway. Xu L; Li J; Hou N; Han F; Sun X; Li Q Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):688-696. PubMed ID: 38584523 [TBL] [Abstract][Full Text] [Related]
30. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357 [TBL] [Abstract][Full Text] [Related]
31. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. Meng P; Zhang YF; Zhang W; Chen X; Xu T; Hu S; Liang X; Feng M; Yang X; Ho M Sci Rep; 2021 Jan; 11(1):40. PubMed ID: 33420124 [TBL] [Abstract][Full Text] [Related]
32. Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression. Wang B; Xian J; Zang J; Xiao L; Li Y; Sha M; Shen M Biochem Biophys Res Commun; 2019 Jan; 509(1):143-147. PubMed ID: 30573358 [TBL] [Abstract][Full Text] [Related]
33. The role and mechanism of HIF-1α-mediated glypican-3 secretion in hypoxia-induced tumor progression in hepatocellular carcinoma. Wang P; Tong K; Li Y; Li X; Zhang Y; Gu J; Lei P; Yan S; Hu P Cell Signal; 2024 Feb; 114():111007. PubMed ID: 38081444 [TBL] [Abstract][Full Text] [Related]
34. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Zhou F; Shang W; Yu X; Tian J Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802 [TBL] [Abstract][Full Text] [Related]
35. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341 [TBL] [Abstract][Full Text] [Related]
36. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615 [TBL] [Abstract][Full Text] [Related]
37. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748 [TBL] [Abstract][Full Text] [Related]
38. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Sun CK; Chua MS; He J; So SK Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365 [TBL] [Abstract][Full Text] [Related]
39. Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma. Wang D; Gao Y; Zhang Y; Wang L; Chen G Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31160489 [TBL] [Abstract][Full Text] [Related]
40. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. Akutsu N; Yamamoto H; Sasaki S; Taniguchi H; Arimura Y; Imai K; Shinomura Y World J Gastroenterol; 2010 Jul; 16(28):3521-8. PubMed ID: 20653060 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]